Population-Wide Smallpox Vaccination Urged At Senate Hearing
This article was originally published in The Pink Sheet Daily
Smallpox vaccination should be reinstated for the entire U.S. population, MIT’s Deutch suggests. Additional research on other biological threats is called for; federal funding is recommended instead of relying on industry initiative, due to lack of market incentives.
You may also be interested in...
The Senate Appropriations/Homeland Security Subcommittee chairman indicates he may consider stronger liability protections for flu vaccine manufacturers in S 3, his biodefense bill.
Biologic to treat side effects of smallpox vaccination clears FDA based on efficacy data from previously marketed vaccinia immune globulin product. DynPort agrees to conduct a study of the first 100 patients treated as part of accelerated approval post-marketing commitments.
Securities & Exchange Commission regulations on revenue recognition are preventing childhood vaccine manufacturers from selling product to a government stockpile. Rep. Waxman declares support for a special exemption for vaccine makers.